scholarly journals Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy

Medicine ◽  
2021 ◽  
Vol 100 (33) ◽  
pp. e26850
Author(s):  
Yalei Lv ◽  
Mengyuan Xu ◽  
Yidan Sun ◽  
Yezhou Liu ◽  
Lijuan Zhao ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Excision Repair ◽  
Prognostic Significance ◽  
Complementation Group ◽  
Platinum Based Chemotherapy ◽  
Group 1

Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer

2008 ◽  
Vol 18 (5) ◽  
pp. 1007-1012 ◽  
Author(s):  
K. Lin ◽  
D. Ye ◽  
X. Xie
Keyword(s):  
Ovarian Cancer ◽  
Protein Expression ◽  
Clear Cell ◽  
Excision Repair ◽  
Cell Cancer ◽  
Complementation Group ◽  
Serous Ovarian Cancer ◽  
Expression Levels ◽  
Platinum Based Chemotherapy ◽  
Group 1

This study was undertaken to examine whether there is an association between excision repair cross-complementation group 1 (ERCC1) and xeroderma pigmentosum D (XPD) protein expression levels and response to platinum-based chemotherapy in epithelial ovarian cancer (EOC). The study cohort consisted of 91 consecutive patients suffering from stage III or IV disease of primary EOC from 1999 to 2004 at the Women's Hospital, School of Medicine, Zhejiang University. There were 36 sensitive cases of serous ovarian cancer, 27 resistant cases of serous ovarian cancer, 15 cases of clear cell cancer, and 13 cases with serous ovarian cancer receiving neoadjuvant chemotherapy. The ovarian tissue microsections were stained by standard immunohistochemical techniques to show ERCC1 and XPD protein expression levels. In resistance group of serous ovarian cancer, ERCC1 and XPD protein expression levels were significantly higher than those of sensitivity group, and after receiving neoadjuvant chemotherapy, they showed 23% and 32% higher than before. Meanwhile, their levels of clear cell cancer group were significantly higher than serous ovarian cancer group's. Upregulation of ERCC1 and XPD protein expression was associated with resistance process to platinum-based chemotherapy in advanced EOC. This study provided evidence that differences of nucleotide excision repair–related genes expression may have an effect on the observed differences in clinical behavior of EOC

scholarly journals Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis

2015 ◽  
Vol 9 (4) ◽  
pp. 1393-1400 ◽  
Author(s):  
PENG SONG ◽  
QIN YIN ◽  
MING LU ◽  
BO FU ◽  
BAOLIN WANG ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Value ◽  
Excision Repair ◽  
Meta Analysis ◽  
Complementation Group ◽  
Group 1

Expression of excision repair cross-complementation group 1 protein and outcome in patients with nasopharyngeal cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6085-6085
Author(s):  
H. Lee ◽  
Y. Hwang ◽  
J. Han ◽  
J. Choi ◽  
S. Kang ◽  
...  
Keyword(s):  
Excision Repair ◽  
Univariate Analysis ◽  
Locally Advanced ◽  
Prognostic Significance ◽  
Nasopharyngeal Cancer ◽  
Complementation Group ◽  
High Expression ◽  
Significant Independent Predictor ◽  
Group 1

6085 Background: We evaluated the prognostic significance of thymidylate synthase (TS), and Excision Repair Cross-Complementation Group 1 protein (ERCC1) in patients (pts) with nasopharyngeal cancer (NPC) treated with concurrent chemoradiotherapy (CCRT). Methods: Pretreatment tumor biopsy specimens from 41 pts with locally advanced NPC were analyzed for TS and ERCC1 expression by immunohistochemistry. All patients were treated with 1 cycle of induction chemotherapy (5-fluorouracil 1,000 mg/m2/day and cisplatin 20 mg/m2/day, days 1–4) followed by CCRT starting on day 22. CCRT consisted of radiotherapy (70Gy/35 fractions for 7 weeks) with cisplatin 20mg/m2/day for 4 days on weeks 1, 4, 7 of radiotherapy. Results: Complete response and partial response were achieved in 34 pts (83%) and 6 pts (15%), respectively. Within median follow up duration of 101 months (26–147months) in survivors, 5-years overall survival (OS) of all pts was 50%. High expression of TS and ERCC1 was observed in 21 (51%) and 25 (60%) pts, respectively. High expression of ERCC1 was associated with WHO type 1 or 2 histology (p = 0.045). In univariate analysis, high expression of ERCC1 was associated with poor OS (5-year: 73% versus 35%; p = 0.005), while high expression of TS was not correlated with pts outcome (p = 0.867). In multivariate analysis, high expression of ERCC1 was a significant independent predictor of poor OS (p = 0.041) along with WHO type 1 or 2 histology (p = 0.004). Conclusions: High expression of ERCC1 protein may be useful for prediction of poor outcome in pts with NPC treated with CCRT. No significant financial relationships to disclose.

scholarly journals Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer

2008 ◽  
Vol 3 ◽  
pp. BMI.S485 ◽  
Author(s):  
Giannis Mountzios ◽  
Meletios-Athanasios Dimopoulos ◽  
Christos Papadimitriou
Keyword(s):  
Lung Cancer ◽  
Dna Damage ◽  
Dna Adducts ◽  
Excision Repair ◽  
Complementation Group ◽  
Small Cell ◽  
Small Cell Lung ◽  
Platinum Based Chemotherapy ◽  
Ercc1 Expression ◽  
Group 1

Although platinum-based chemotherapy remains the “standard” in advanced non small-cell lung cancer, not all patients derive clinical benefit from such a treatment. Hence, the development of predictive biomarkers able to identify lung cancer patients who are most likely to benefit from cisplatin-based chemotherapy has become a scientific priority. Among the molecular pathways involved in DNA damage control after chemotherapy, the nucleotide excision repair (NER) is a critical process for the repair of DNA damage caused by cisplatin-induced DNA adducts. Many reports have explored the role of the excision repair cross-complementation group 1 enzyme (ERCC1) expression in the repair mechanism of cisplatin-induced DNA adducts in cancer cells. Using immunohistochemistry in resected tumors from patients included in the International Adjuvant Lung Cancer Trial, the study of important biomarkers showed that high ERCC1 protein expression was associated with improved survival in chemo-naïve patients. On the contrary, the benefit of adjuvant cisplatin-based chemotherapy was more profound in patients with low ERCC1 expression. In a prospective cohort studying mRNA expression in tumor biopsies from patients receiving customized therapy with cisplatin and gemcitabine depending on the molecular profile of the tumour, results showed that patients with low ERCC1 mRNA expression had a longer median survival compared to those with high expression. These data suggest the potent use of ERCC1 as a molecular predictor of clinical resistance to platinum-based chemotherapy in the adjuvant setting of NSCLC. Nevertheless, optimization of methodology, including standardization of technical procedures, as well as validation of ERCC1 protein expression in large prospective cohorts, seem necessary before any routine immunohistochemical validation of ERCC1 can be implemented in daily practice.

Sign in / Sign up

Export Citation Format

Share Document